Opendata, web and dolomites

Ru4EYE SIGNED

Ruthenium-based photoactivated chemotherapy against eye cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Ru4EYE project word cloud

Explore the words cloud of the Ru4EYE project. It provides you a very rough idea of what is the project "Ru4EYE" about.

vision    completion    removable    photochemical    agent    market    trials    zebrafish    kill    risky    efficacy    solution    liver    independent    hypoxic    starting    reaction    agents    evaluation    protecting    presentation    xenografts    uveal    toxicity    light    appears    ru4eye    compounds    vivo    photosensitive    grant    vitro    rare    exist    relatively    disease    site    diseases    ru    venture    bioactive    translational    tumor    driving    preserve    monolayers    biological    first    proof    translation    cells    action    clinics    nature    eye    accelerate    difficult    patients    model    activation    metastasis    capital    positive    erc    embryo    chemotherapy    clinical    death    models    treatment    cancer    selectively    mouse    normoxic    pact    photoactivated    mechanism    solutions    form    dioxygen    appealing    treat    patient    2d    3d    oxygen    irradiation    complete    melanoma    spheroids    always    cytotoxic    start    breakage    ruprolight    drug    series    phototherapy    malignancy    group    save    innovative    bond    um    performed    poc    therapeutic   

Project "Ru4EYE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

The Ru4EYE PoC proposal will develop the first pre-clinical evaluation of Ru-based PACT compounds in uveal melanoma (UM) model. UM is a rare malignancy of the eye. Although treatment against UM do exist, they do no always preserve vision or the eye, and often lead to patient death via metastasis to the liver. A better treatment that would save vision, the eye, and the patient, is looked after. UM appears as an appealing disease for photoactivated chemotherapy (PACT), a new form of phototherapy developed within my ERC Starting Grant RuProLight. PACT agents are photosensitive compounds that can kill cancer cells selectively under the action of light. In PACT dioxygen does not need to be present at the site of light irradiation because the mechanism of photochemical activation is an oxygen-independent bond breakage reaction between a bioactive, cytotoxic agent, and a light-removable protecting group. Innovative therapeutic solutions such as PACT are typically difficult to bring to the market because of the risky nature of drug development and the funding required for clinical trials. The vision in this grant proposal is that positive results on a rare form of cancer such as uveal melanoma could not only offer a relatively short-term solution to uveal melanoma patients, but also accelerate translation of Ru-based PACT to the clinics by driving developments for other diseases as well. The biological testing of Ru-based PACT compounds will be performed in a complete series of translational cancer models: from in vitro (2D monolayers of normoxic and hypoxic cancer cells, 3D tumor spheroids) to in vivo (xenografts in zebrafish embryo for studying metastasis formation and treatment, and mouse model for in vivo toxicity and efficacy). The aim is to develop a pre-clinical proof-of-concept that PACT can be used to treat uveal melanoma, so that presentation to venture capital and clinical testing can start quickly after completion of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RU4EYE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RU4EYE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

NeuroMag (2019)

The Neurological Basis of the Magnetic Sense

Read More  

RTMFRM (2019)

Room Temperature Magnetic Resonance Force Microscopy

Read More